The estimated Net Worth of Frank D. Lee is at least 3.3 百万$ dollars as of 12 August 2024. Mr Lee owns over 8,264 units of Forma Therapeutics stock worth over 2,156,758$ and over the last 4 years he sold FMTX stock worth over 175,854$. In addition, he makes 963,198$ as Pres、 CEO & Director at Forma Therapeutics.
Mr has made over 2 trades of the Forma Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 8,264 units of FMTX stock worth 99,994$ on 12 August 2024.
The largest trade he's ever made was selling 17,981 units of Forma Therapeutics stock on 23 February 2022 worth over 175,854$. On average, Mr trades about 3,281 units every 113 days since 2020. As of 12 August 2024 he still owns at least 107,784 units of Forma Therapeutics stock.
You can see the complete history of Mr Lee stock trades at the bottom of the page.
Frank D. Lee is the Pres, CEO & Director at Forma Therapeutics.
As the Pres、 CEO & Director of Forma Therapeutics, the total compensation of Mr Lee at Forma Therapeutics is 963,198$. There are no executives at Forma Therapeutics getting paid more.
Mr Lee is 53, he's been the Pres、 CEO & Director of Forma Therapeutics since . There are 6 older and 1 younger executives at Forma Therapeutics. The oldest executive at Forma Therapeutics Holdings, Inc., is Dr. David N. Cook Ph.D., 63, who is the Sr. VP & Chief Scientific Officer.
Frank's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 4 years, insiders at Forma Therapeutics have traded over 446,330$ worth of Forma Therapeutics stock and bought 9,000,000 units worth 180,000,000$ . The most active insiders traders include Capital Management, L.P.Ra ...、Peter Kolchinsky、Capital Management, L.P.Ra .... On average, Forma Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of 10,575,905$. The most recent stock trade was executed by Patrick F. Kelly on 13 April 2022, trading 15,000 units of FMTX stock currently worth 75,750$.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.
Forma Therapeutics executives and other stock owners filed with the SEC include: